KRAS and colorectal carcinoma: In contrast, the CALGB 89803 and PETACC-3 trials demonstrated that KRAS mutation status had no significant effect on recurrence or OS in patients with stage II/III colon cancer or CRC treated with adjuvant chemotherapy [12, 16].